**Global Angina Market Research Report, by Type (Angina Pectoris), Diagnosis (Imaging, Stress Test), Treatment (Lifestyle, Medications, Angioplasty, and Stenting), End-Users (Hospital & Clinics, Diagnostic Centers, Academic Institutes)–Forecast Till 2023**

**Market Scenario**

Angina is a significant symptom of the coronary artery disease and is described as squeezing, tightness, and heaviness of the chest. It is a type of chest pain, which is caused by a reduced flow of blood to the heart. Fatigue, shortness of breath, nausea, and sweating are some of the common symptoms of angina. The increasing prevalence of angina and the growing healthcare expenditure are the major drivers for the market growth. According to the report of the American Heart Association of 2016, the prevalence of angina in West Virginia was estimated to be around 6.2% and around 2.3% in Hawaii. Moreover, the growing geriatric and obese population followed by the increasing prevalence of coronary heart diseases provide favorable backgrounds for market growth. According to the World Health Organization, the total number of people who age 65 or more is projected to increase from 524 million in 2010 to approximately 1.5 billion by 2050. Additionally, according to a study published in the Annals of Translational Medicine Journal approximately 15.5 million people who aged 20 years or more within the U.S. suffered from the coronary heart disease, in 2016. However, factors such as low per capita healthcare expenditure and high cost for therapeutic procedures such as coronary bypass surgery are estimated to restraint the market growth during the forecast period. According to a study published by the Brazilian Journal of Cardiovascular Surgery in 2017, the average total cost for coronary bypass surgery was estimated to be ~USD 7,992.

*Global Angina Market is expected to grow at an approximate CAGR of 5.1% during the forecast period.*

**Intended Audience**

- Pharmaceutical Companies
- Biotechnological Institutes
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Market Research and Consulting Service Providers

*Figure 1: - Global Angina Market Share, by Region*
Segmentation

The global angina Market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the market is segmented into angina pectoris, unstable angina, prinzmetal angina, and others. On the basis of diagnosis, the market is categorized into imaging, blood test, stress test, and others. The imaging segment is sub-segmented into electrocardiogram, chest X-ray, cardiac computerized tomography scan, cardiac MRI, and others. The blood test segment is sub-segmented into cholesterol test, low-density lipoprotein test, triglycerides test, and others. On the basis of treatment, the market is segmented into lifestyle changes, medications, angioplasty and stenting, coronary bypass surgery, and others. The medication segment is sub-segmented into aspirin, clot-preventing drugs, statins, ranolazine, and others. The clot-preventing drugs segment is further segmented into clopidogrel, prasugrel, and others. On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, academic institutes, and others.

Research Methodology
Regional Analysis

America dominates the global angina market owing to a well-developed healthcare sector, growing healthcare expenditure, and a huge patient population for coronary heart diseases. Moreover, global players such as Merck & Co., Inc. and Baxter within the region fuel the market growth.

Europe is the second largest market for angina. Factors such as availability of funds for research, growing number of obese and patient population, followed by the presence of developed economies such as France, Italy, and Germany within the region provide favorable backgrounds for regional market growth. According to the Eurostat in 2016, it was estimated that more than half of the adult population (51.6%) within the European Union was overweight.

Asia Pacific is estimated to be the fastest growing region for the global angina market owing to the presence of developing economies such as India and China and a developing healthcare sector. Moreover, rising healthcare expenditure and favorable government policies are expected to boost the market growth during the forecast period.

The Middle East and Africa holds the least share in the global angina market, owing to the presence of poor economies, stringent government policies, and low per capita healthcare expenditure, especially within the African region. A majority of the market of the region is held by the Middle East owing to the increasing healthcare expenditure and presence of developed economies such as Saudi Arabia, Kuwait, and Qatar within the region.

Key players in the Global Angina Market

Anthera (U.S.), Taxus Cardium (U.S.), Astellas Pharma (Japan), Sanofi (France), Bayer AG (Germany), Merck & Co., Inc. (U.S.), Torrent Pharmaceuticals Limited (India), Huya Bioscience International (U.S.), Viromed Co. Ltd. (South Korea), Baxter (U.S.), and others.
TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations

Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation

Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

Chapter 6. Global Angina Market, by Type
6.1 Introduction
6.2 Angina Pectoris
Market Estimates & Forecast, 2017–2023
6.3 Unstable Angina
Market Estimates & Forecast, 2017–2023
6.4 Prinzmetal Angina
Market Estimates & Forecast, 2017–2023
6.5 Others

Chapter 7. Global Angina Market, by Diagnosis
7.1 Introduction
7.2 Imaging
Market Estimates & Forecast, 2017–2023
7.2.1 Electrocardiogram
7.2.2 Chest X-ray
7.2.3 Cardiac Computerized Tomography Scan
7.2.4 Cardiac MRI
7.2.5 Others
7.3 Blood Tests
Market Estimates & Forecast, 2017–2023
7.3.1 Cholesterol Test
7.3.2 Low-Density Lipoprotein Test
7.3.3 Triglycerides Test
7.3.4 Others
7.4 Stress Test
Market Estimates & Forecast, 2017–2023
7.5 Others

Chapter 8. Global Angina Market, by Treatment
8.1 Introduction
8.2 Lifestyle Changes
Market Estimates & Forecast, 2017–2023
8.3 Medications
Market Estimates & Forecast, 2017–2023
8.3.1 Aspirin
8.3.2 Clot-Preventing Drugs
Market Estimates & Forecast, 2017–2023
8.3.2.1 Clopidogrel
8.3.2.2 Prasugrel
8.3.2.3 Others
8.3.3 Statins
8.3.4 Ranolazine
8.3.5 Others
8.4 Angioplasty and Stenting
Market Estimates & Forecast, 2017–2023
8.5 Coronary Bypass Surgery
Market Estimates & Forecast, 2017–2023
8.6 Others

Chapter 9. Global Angina Market, by End-User
9.1 Introduction
9.2 Hospital & Clinics
Market Estimates & Forecast, 2017–2023
9.3 Diagnostic Centers
Market Estimates & Forecast, 2017–2023
9.4 Academic Institutes
Market Estimates & Forecast, 2017–2023
9.5 Others

Chapter 10. Global Angina Market, by Region
10.1 Introduction
10.2 America
10.2.1 North America
10.2.1.1 U.S.
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 U.K.
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa

Chapter 11. Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments

Chapter 12 Company Profiles
12.1 Anthera
12.1.1 Company Overview
12.1.2 Type Overview
12.1.3 Financials
12.2.4 Key Developments
12.1.5 SWOT Analysis
12.2 Taxus Cardium
12.2.1 Company Overview
12.2.2 Type Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Astellas Pharma
12.3.1 Company Overview
12.3.2 Type Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Sanofi
12.4.1 Company Overview
12.4.2 Type/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 Bayer AG
12.5.1 Company Overview
12.5.2 Type Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.5.5 SWOT Analysis
12.6 Merck & Co., Inc.
12.6.1 Company Overview
12.6.2 Type Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.6.5 SWOT Analysis
12.7 Torrent Pharmaceuticals
12.7.1 Overview
12.7.2 Type Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 Huya Bioscience International
12.8.1 Overview
12.8.2 Type Overview
12.8.3 Financials
12.8.4 Key Developments
12.8.5 SWOT Analysis
12.9 Viromed Co. Ltd.
12.9.1 Overview
12.9.2 Type Overview
12.9.3 Financials
12.9.4 Key Developments
12.9.5 SWOT Analysis
12.10 Baxter
12.10.1 Overview
12.10.2 Type Overview
12.10.3 Financials
12.10.4 Key Developments
12.10.5 SWOT Analysis
12.11 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings
13.1.1 From CEO’s View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of Angina Market

Chapter 14 Appendix

LIST OF TABLES
Table 1 Angina Industry Synopsis, 2017–2023
Figure 6 Global Angina Market Share, by Treatment, 2016
Figure 7 Global Angina Market Share, by End-User, 2016
Figure 8 Global Angina Market Share, by Region, 2016
Figure 9 North America Angina Market Share, by Country, 2016
Figure 10 Europe Angina Market Share, by Country, 2016
Figure 11 Asia Pacific Angina Market Share, by Country, 2016
Figure 12 The Middle East & Africa Angina Market Share, by Country, 2016
Figure 13 Global Angina Market: Company Share Analysis, 2016 (%)
Figure 14 Anthera: Key Financials
Figure 15 Anthera: Segmental Revenue
Figure 16 Anthera: Geographical Revenue
Figure 17 Taxus Cardium: Key Financials
Figure 18 Taxus Cardium: Segmental Revenue
Figure 19 Taxus Cardium: Geographical Revenue
Figure 20 Astellas Pharma: Key Financials
Figure 21 Astellas Pharma: Segmental Revenue
Figure 22 Astellas Pharma: Geographical Revenue
Figure 23 Sanofi: Key Financials
Figure 24 Sanofi: Segmental Revenue
Figure 25 Sanofi: Geographical Revenue
Figure 26 Bayer AG: Key Financials
Figure 27 Bayer AG: Segmental Revenue
Figure 28 Bayer AG: Geographical Revenue
Figure 29 Merck & Co., Inc.: Key Financials
Figure 30 Merck & Co., Inc.: Segmental Revenue
Figure 31 Merck & Co., Inc.: Geographical Revenue
Figure 32 Torrent Pharmaceuticals Limited: Key Financials
Figure 33 Torrent Pharmaceuticals Limited: Segmental Revenue
Figure 34 Torrent Pharmaceuticals Limited: Geographical Revenue
Figure 35 Huya Bioscience International: Key Financials
Figure 36 Huya Bioscience International: Segmental Revenue
Figure 37 Huya Bioscience International: Geographical Revenue
Figure 38 Viromed Co. Ltd.: Key Financials
Figure 39 Viromed Co. Ltd.: Segmental Revenue
Figure 40 Viromed Co. Ltd.: Geographical Revenue
Figure 41 Baxter: Key Financials
Figure 42 Baxter: Segmental Revenue
Figure 43 Baxter: Geographical Revenue